Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Scott A. Armstrong, M.D.,Ph.D.

Co-Author

This page shows the publications co-authored by Scott Armstrong and Stephen Sallan.
Connection Strength

0.624
  1. Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia. Nat Commun. 2014 Mar 24; 5:3469.
    View in: PubMed
    Score: 0.151
  2. Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell. 2006 Oct; 10(4):331-42.
    View in: PubMed
    Score: 0.090
  3. FLT3 mutations in childhood acute lymphoblastic leukemia. Blood. 2004 May 01; 103(9):3544-6.
    View in: PubMed
    Score: 0.074
  4. Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell. 2003 Feb; 3(2):173-83.
    View in: PubMed
    Score: 0.070
  5. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet. 2002 Jan; 30(1):41-7.
    View in: PubMed
    Score: 0.064
  6. Association of high-level MCL-1 expression with in vitro and in vivo prednisone resistance in MLL-rearranged infant acute lymphoblastic leukemia. Blood. 2010 Feb 04; 115(5):1018-25.
    View in: PubMed
    Score: 0.028
  7. BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. Blood. 2008 Feb 15; 111(4):2300-9.
    View in: PubMed
    Score: 0.024
  8. Genomewide identification of prednisolone-responsive genes in acute lymphoblastic leukemia cells. Blood. 2007 May 01; 109(9):3929-35.
    View in: PubMed
    Score: 0.023
  9. Silencing of the tumor suppressor gene FHIT is highly characteristic for MLL gene rearranged infant acute lymphoblastic leukemia. Leukemia. 2006 Feb; 20(2):264-71.
    View in: PubMed
    Score: 0.021
  10. Gene expression profiling identifies BAX-delta as a novel tumor antigen in acute lymphoblastic leukemia. Cancer Res. 2005 Nov 01; 65(21):10050-8.
    View in: PubMed
    Score: 0.021
  11. Distinctive IGH gene segment usage and minimal residual disease detection in infant acute lymphoblastic leukaemias. Br J Haematol. 2005 Oct; 131(2):185-92.
    View in: PubMed
    Score: 0.021
  12. Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia. Blood. 2005 Oct 01; 106(7):2484-90.
    View in: PubMed
    Score: 0.020
  13. Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation. Blood. 2003 Jul 01; 102(1):262-8.
    View in: PubMed
    Score: 0.018
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.